Metformin could induce G0/G1 cell cycle arrest and impair RCC growth in vitro and in vivo by inhibiting the AKT/mTOR pathway, while Sunitinib and Sorafenib suppress cell proliferation and angiogenesis by targeting VEGF and PDGF receptors [112,113]. Here, MTOR is linked to renal cell carcinoma.